What is the 13F Pro Quality Score for ELDN?

13F Pro ranks Eledon Pharmaceuticals, Inc. (ELDN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ELDN's current score at https://13fpro.ai/company/ELDN (free sign-up required for the full ranking).

Which hedge funds own the most ELDN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ELDN include BVF /IL, BlackRock,, Defilade Capital Management, L.P.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ELDN as soon as new 13F filings post.

Where does 13F Pro source ELDN data?

All Eledon Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Eledon Pharmaceuticals, Inc. files with the SEC under CIK 1404281. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ELDN in?

Eledon Pharmaceuticals, Inc. (ELDN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ELDN research updated on 13F Pro?

ELDN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Eledon Pharmaceuticals, Inc.(ELDN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1404281 ELDN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

ELDN Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Eledon Pharmaceuticals, Inc. (ELDN), a Healthcare sector company. ELDN is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of ELDN by reported 13-F value include BVF, BlackRock, Defilade Capital Management, L.P., based on the most recent SEC filings. ELDN trades on the Nasdaq exchange and files with the SEC under CIK 1404281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELDN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Eledon Pharmaceuticals, Inc. directly from SEC EDGAR.

✦

Fun facts about Eledon Pharmaceuticals, Inc.

Quirks, history, and lore behind ELDN — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage pharmaceutical company · micro-cap · listed on Nasdaq · operating in the drug development space.
2
The Numbers
With a market cap in the micro-cap range, this company generates little to no revenue — typical of a clinical-stage biotech burning cash while chasing FDA approval.
3
The History
Like many small biotechs, it has undergone name changes and rebranding over its corporate life, reflecting shifts in its pipeline focus and strategy.
4
The Secret
Its survival depends entirely on capital raises and the outcome of clinical trials — the classic high-risk, high-reward biotech gamble.
5
The Lore
A tiny company with a ticker most investors have never heard of, yet its researchers show up every day betting they can move a drug from bench to bedside.
6
The Giveaway
The ticker is ELDN — and this Eledon-named pharma is about as niche as it gets on the Nasdaq small-cap healthcare shelf.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-31.6M

D/E Ratio

Q2 2026

0.00

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

-26.1% YoY

$-45.6MFY 2025

FY22 $-88.0MFY23 $-116.5MFY24 $-36.2MFY25 $-45.6M

Operating Income

—FY 2025

FY22 $-88.4MFY23 $-43.0MFY24 —FY25 —

EPS (Diluted)

+21.2% YoY

$-0.52FY 2025

FY22 $-6.16FY23 $-4.73FY24 $-0.66FY25 $-0.52

Total Assets

-4.7% YoY

$169.0MFY 2025

FY22 $92.8MFY23 $89.1MFY24 $177.4MFY25 $169.0M

Total Debt

$0.00FY 2025

FY22 $0.00FY23 $0.00FY24 $0.00FY25 $0.00

Op. Cash Flow

-31.9% YoY

$-62.3MFY 2025

FY22 $-28.4MFY23 $-39.5MFY24 $-47.3MFY25 $-62.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-45.6M -26.1%	$-36.2M +69.0%	$-116.5M -32.5%	$-88.0M -154.9%	$-34.5M -51.3%	$-22.8M
Operating Income	—	—	$-43.0M +51.4%	$-88.4M -139.9%	$-36.9M -99.7%	$-18.5M
EPS (Diluted)	$-0.52 +21.2%	$-0.66 +86.0%	$-4.73 +23.2%	$-6.16 -164.4%	$-2.33	—
Total Assets	$169.0M -4.7%	$177.4M +99.2%	$89.1M -4.0%	$92.8M -45.6%	$170.5M -13.5%	$197.2M
Total Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Operating Cash Flow	$-62.3M -31.9%	$-47.3M -19.6%	$-39.5M -39.1%	$-28.4M +1.7%	$-28.9M -90.1%	$-15.2M

Get alerted when ELDN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Eledon Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ELDN

BVF INC/IL
$24.8M6,293,282 sh
BlackRock, Inc.
$20.2M5,123,842 sh
Defilade Capital Management, L.P.
$13.9M3,525,338 sh
VANGUARD CAPITAL MANAGEMENT LLC
$13.5M3,417,223 sh
GOLDMAN SACHS GROUP INC
$9.9M2,510,308 sh
Ensign Peak Advisors, Inc
$8.3M2,101,224 sh
GEODE CAPITAL MANAGEMENT, LLC
$7.7M1,956,601 sh
Catalio Capital Management, LP
$6.7M1,695,071 sh
STATE STREET CORP
$6.4M1,621,969 sh
Zimmer Partners, LP
$6.3M1,596,599 sh

Fund	Value	Shares
BVF INC/IL	$24.8M	6,293,282
BlackRock, Inc.	$20.2M	5,123,842
Defilade Capital Management, L.P.	$13.9M	3,525,338
VANGUARD CAPITAL MANAGEMENT LLC	$13.5M	3,417,223
GOLDMAN SACHS GROUP INC	$9.9M	2,510,308
Ensign Peak Advisors, Inc	$8.3M	2,101,224
GEODE CAPITAL MANAGEMENT, LLC	$7.7M	1,956,601
Catalio Capital Management, LP	$6.7M	1,695,071
STATE STREET CORP	$6.4M	1,621,969
Zimmer Partners, LP	$6.3M	1,596,599

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ELDN on your watchlist

Track score changes the day Eledon Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ELDN a good stock to buy?

13F Pro's AI-powered analysis of Eledon Pharmaceuticals, Inc. (ELDN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELDN are available on the ELDN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ELDN is classified as a small company.

Which hedge funds own ELDN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELDN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Eledon Pharmaceuticals, Inc.'s investment landscape.